Eckert & Ziegler Eurotope GmbH (Eurotope) and Moltek, Inc. (Moltek) have signed a collaborative development agreement to join forces for the development of automated processes and the conduct of studies for promising radiopharmaceuticals on Eurotope’s proprietary synthesis and quality control platforms. Under the agreement Eurotope will provide Modular-Lab and QC systems for Moltek to develop and automate processes for a pre-defined number of innovative radiotracers for distribution on the Turkish market.

“Turkey is a key market for our business. We are glad to intensify activities with the Moltek team, who have proven to be a reliable and capable partner in the past years” stated Dr. Sven-Peter Heyn, general manager of Eckert & Ziegler Eurotope GmbH. “With their comprehensive market and radiochemistry knowhow we will secure access to innovative radiopharmaceutical products for Turkish nuclear medicine practices and clinics.”

“The Turkish nuclear medicine market is continuously growing and so is the demand for new diagnostic and therapeutic solutions” stated Can Zafer Aksoy, Chief Commercial Officer of Moltek, Inc. “By making available promising new tracers for routine production and distributing these in Turkey, using state-of-the-art equipment from Eckert & Ziegler, we contribute our share to improve the quality of life for patients living with different diseases.”

“Being one of the strongest in the world, the Turkish Nuclear Medicine Society (TSNM) is quite open to innovative applications with new tracers especially from the theranostics field. Ga-68 and Lu-177 applications being carried out since 2007 and reimbursed since 2009, demonstrate the attention of TSNM to innovation. Collaborating on innovative tracers with Eckert & Ziegler as one of the world’s leading companies will sharpen our tools in the battle with fatal diseases not only in Turkey but worldwide. Thus, we are proud to announce our collaborative development agreement for a healthier future and hope to bring forth more tracers to the world market with continuous R&D projects.” stated Kadir Ozsu, Chief Executive Officer of Moltek, Inc.

About Eckert & Ziegler Eurotope GmbH

Eurotope GmbH belongs to the Eckert & Ziegler group and represents the Lab Devices business unit of the Medical Segment. The company develops, manufactures and sells systems and accessories for radionuclide labeling and quality control of radiopharmaceuticals. The products are used in research and routine manufacturing of patient doses for cancer diagnosis and therapy in hospitals as well as in industrial manufacturing processes for radioactively labeled compounds and drugs.

As part of the Medical Segment, Eurotope GmbH contributes to provide complete solutions to Eckert & Ziegler´s worldwide customers in the nuclear medicine and pharma industry. The comprehensive product and service portfolio ranges from customized hot cell solutions and in-cell equipment over radionuclides to contract development and GMP-manufacturing services for radiopharmaceuticals through all stages from early clinical to commercial supply.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world’s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.